

CLAIMS

1. A vaccine composition comprising:
 - a) a protein comprising at least one epitope of human ST receptor protein or a nucleic acid molecule that encodes said protein; and
 - b) a pharmaceutically acceptable carrier or diluent.
2. The vaccine composition of claim 1 comprising said protein wherein said protein an epitope of the extracellular domain of the human ST receptor protein.
3. The vaccine composition of claim 2 comprising said protein wherein said protein comprises the extracellular domain of the human ST receptor protein.
4. The vaccine composition of claim 3 comprising said protein wherein the protein comprises the human ST receptor protein.
5. The vaccine composition of claim 4 comprising said protein wherein the protein consists of the human ST receptor protein.
6. The vaccine composition of claim 1 comprising a nucleic acid molecule that encodes said protein wherein said protein comprises an epitope of the extracellular domain of the human ST receptor protein.
7. The vaccine composition of claim 6 comprising a nucleic acid molecule that encodes said protein wherein said protein comprises the extracellular domain of the human ST receptor protein.

8. The vaccine composition of claim 7 comprising a nucleic acid molecule that encodes said protein wherein the protein comprises the human ST receptor protein.

9. The vaccine composition of claim 8 comprising a
5 nucleic acid molecule that encodes said protein wherein the protein consists of the human ST receptor protein.

10. The vaccine composition of claim 1 comprising a nucleic acid molecule that encodes said protein wherein said
10 nucleic acid molecule is a plasmid.

11. The vaccine composition of claim 1 comprising a nucleic acid molecule that encodes said protein wherein said nucleic acid molecule is within a viral vector or a bacterial cell.

12. The vaccine composition of claim 11 wherein said
15 viral vector is a recombinant vaccinia virus.

13. A haptenized protein comprising at least one epitope of human ST receptor protein.

14. The haptenized protein of claim 13 wherein said
20 protein comprises at least one epitope of the extracellular domain of the human ST receptor protein.

15. The haptenized protein of claim 14 wherein said protein comprises the extracellular domain of the human ST receptor protein.

16. The haptenized protein of claim 15 wherein the
25 protein comprises the human ST receptor protein.

17. A vaccine composition that comprises a haptenized protein of claim 13 and a pharmaceutically acceptable carrier or diluent.

18. A vaccine composition comprising killed or inactivated cells or particles that comprise a protein comprising at least one epitope of human ST receptor protein and a pharmaceutically acceptable carrier or diluent.

5

19. The vaccine of claim 18 wherein said killed or inactivated cells or particles comprise a protein with an epitope of the extracellular domain of the human ST receptor protein.

10 20. The vaccine of claim 19 wherein said killed or inactivated cells or particles comprise a protein with the extracellular domain of the human ST receptor protein.

21. The vaccine of claim 20 wherein said killed or inactivated cells or particles comprise the human ST receptor
15 protein.

22. The vaccine of claim 21 wherein said killed or inactivated cells or particles comprise killed or inactivated colorectal tumor cells.

23. The vaccine of claim 18 wherein said killed or
20 inactivated cells or particles are haptenized killed or inactivated cells or particles.

24. A method of treating an individual who has metastasized colorectal cancer comprising the step of administering to such an individual a therapeutically effective
25 amount of a vaccine of claim 1.

25. A method of treating an individual who has been identified as being susceptible to metastasized colorectal cancer comprising the step of administering to such an individual a prophylactically effective amount of a vaccine of
30 claim 1.